SLC5A3 and familial pancreatic carcinoma: Therefore, strategies targeting SLC5A3 can be used as novel therapeutic approaches for gemcitabine-resistant pancreatic cancer by enhancing tumor suppression and alleviating mitochondrial dysfunction.